Day 1 | Day 2
Join scientific colleagues for discussions around risks and progress in the field of type 2 diabetes drug discovery and development. From podium presentations, an 'expert' panel session, roundtable breakout discussions and networking opportunities you will be able to:
-Keep abreast of progress on SGLT2 inhibitors and other anti-diabetes drug candidates
-Ask questions of panelists discussing 'Diabetes Drug Development Challenges'
-Learn about gastric by-pass proteins and other new targets for diabetes drugs
-Participate and problem-solve in a small group discussion on a focused topic of interest to you
Please also join us for a special dinner short course* on Targeting Pancreatic Islets for Type 2 Diabetes(click here), one of the newest areas of diabetes research, which takes place on the evening of the first day of the meeting, Nov. 3rd.
*separate registration required
THURSDAY, NOVEMBER 3
1:30 pm Chairperson's Remarks
Rebecca Taub, M.D., CEO, Madrigal Pharmaceuticals
1:40 FEATURED PRESENTATION:
Inhibiting Glucose Transporters via SGLT inhibitors – the Next New Diabetes Drug Family?
 Michael Mark, Ph.D., Vice President, CardioMetabolic Diseases Research, Boehringer Ingelheim
This presentation will provide an update on diabetes drug candidates in late stage development, with a focus on compounds targeting sodium glucose transporters. Current challenges faced in the field of diabetes drug development will also be covered.
|
2:25 FEATURED PRESENTATION:
Diabetes Drug Targets from Gastric Bypass Surgery
 Lee M. Kaplan, M.D., Ph.D., Professor, Harvard Medical School
|
3:10 Networking Refreshment Break in the Exhibit Hall with Poster Viewing
3:45 A Physician’s Perspective on the Future of Diabetes Treatments
Rohit N. Kulkarni, M.D., Ph.D., Associate Professor, Medicine, Harvard Medical School; Investigator, Joslin Diabetes Center
This presentation will discuss the scope of the global diabetes problem and which types of diabetes treatments are most needed from a diabetes physician’s and his patients’ perspective to help provide a relevant context to scientists developing new diabetes treatments.
Sponsored by
4:15 Preclinical Research Models of Diabetes and Their Use in Efficacy Assessment of Therapeutics
David S. Grass, Ph.D., Vice President, Scientific Operations, Taconic
To address the challenges facing the biopharmaceutical industry, Taconic was one of the first to develop and validate a broad, in vivo focused platform, which utilizes cost-efficient mice to comprehensively characterize drug development candidates and/or genetic targets. One of the strengths of this program is the ability to characterize genetic targets and potential therapeutics impacting metabolic disorders. Specifically, a variety of models exist for diabetes, simulating the disease condition by affecting various glucoregulatory pathways.
4:30 A GLP1 Positive Allosteric Modulators Approach for the Treatment of Type-2 Diabetes
Guillaume Duvey, Ph.D., Group Leader, Medicinal Chemistry, Addex Pharmaceuticals
4:45 Diabetes Market Landscape
Kelly Close, MBA, President, Close Concerns
5:15 Panel Discussion: Diabetes Drug Development
Moderator:  Rebecca Taub, M.D., CEO, Madrigal Pharmaceuticals
Panelists:
Kelly Close, MBA, President, Close Concerns
Rohit N. Kulkarni, M.D., Ph.D., Associate Professor, Medicine, Harvard Medical School; Investigator, Joslin Diabetes Center
Lee M. Kaplan, M.D., Ph.D., Professor, Harvard Medical School
Cristina Rondinone, Ph.D., Vice President, R&D, Head, Cardiovascular/Metabolic Diseases, MedImmune
Developing diabetes drugs in Asia – how is it different? Is that the future? What will clinical trials look like five years from now? What is the ideal diabetes treatment regimen?
|
5:45 End of Day
Please also join us for a special dinner short course* on Targeting Pancreatic Islets for Type 2 Diabetes(click here), one of the newest areas of diabetes research, which takes place on the evening of the first day of the meeting, Nov. 3rd.
*separate registration required
Day 1 | Day 2 | Download Agenda